Paul Y. Kwo
YOU?
Author Swipe
View article: <b>Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: Are We Doing Enough?</b>
<b>Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: Are We Doing Enough?</b> Open
OBJECTIVE. Patients with type 2 diabetes are at an elevated risk for metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis. Multiple professional societies recommend initiating screening with a fibrosi…
View article: <b>Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: Are We Doing Enough?</b>
<b>Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: Are We Doing Enough?</b> Open
OBJECTIVE. Patients with type 2 diabetes are at an elevated risk for metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis. Multiple professional societies recommend initiating screening with a fibrosi…
View article: Oculometric Assessment of Sensorimotor Impairment Associated with Liver Disease Is as Sensitive as Standard of Care Cognitive Tests
Oculometric Assessment of Sensorimotor Impairment Associated with Liver Disease Is as Sensitive as Standard of Care Cognitive Tests Open
Significance: Hepatic encephalopathy (HE) occurs in 20–80% of patients with liver cirrhosis, impacting attention, memory, processing speed, and visuospatial skills. HE standard-of-care psychometric assessments are time-consuming and requir…
View article: Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome‐Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase <scp>III</scp> Clinical Studies
Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome‐Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase <span>III</span> Clinical Studies Open
Background Terlipressin is the FDA‐approved systemic vasoconstrictor therapy for hepatorenal syndrome‐acute kidney injury (HRS‐AKI)—a rapidly progressive renal failure occurring in patients with decompensated cirrhosis and ascites. Bradyca…
View article: Increasing Trends on Intercostal Chest Tube Placement for Hepatic Hydrothorax Despite Negative Impact on Patient Outcomes: A National Inpatient Sample Database Analysis
Increasing Trends on Intercostal Chest Tube Placement for Hepatic Hydrothorax Despite Negative Impact on Patient Outcomes: A National Inpatient Sample Database Analysis Open
INTRODUCTION: Hepatic hydrothorax (HH) significantly contributes to morbidity in decompensated cirrhosis. Intercostal chest tube (ICT) insertion is discouraged in HH management. We examined trends in ICT use and impact on outcomes in hospi…
View article: The impact of liver transplantation on endpoint selection in alcohol-associated hepatitis trials
The impact of liver transplantation on endpoint selection in alcohol-associated hepatitis trials Open
Background: Alcohol-associated hepatitis (AH) is a serious liver disease caused by heavy alcohol consumption with severe cases exhibiting a 90-day mortality rate of ~30%. No drugs have been approved for AH, and regulatory approval currentl…
View article: Changes in the liver transplant evaluation process during the early COVID-19 era and the role of telehealth
Changes in the liver transplant evaluation process during the early COVID-19 era and the role of telehealth Open
BACKGROUND Coronavirus disease 2019 (COVID-19) disrupted healthcare and led to increased telehealth use. We explored the impact of COVID-19 on liver transplant evaluation (LTE). AIM To understand the impact of telehealth on LTE during COVI…
View article: Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies
Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies Open
Long-term hepatitis C virus (HCV) infection can lead to cirrhosis and liver cancer. Since 2014, these infections can be effectively treated with 8-12 weeks of oral therapies. In 2015, the World Health Organization established targets to el…
View article: Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0
Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0 Open
As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Current…
View article: Hepatocellular Carcinoma Surveillance Following Hepatitis C Virus Cure.
Hepatocellular Carcinoma Surveillance Following Hepatitis C Virus Cure. Open
View article: Response to: Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era
Response to: Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era Open
View article: Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)
Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA) Open
Fazirsiran reduced serum and liver concentrations of Z-AAT in a dose-dependent manner and reduced hepatic globule burden. (ClinicalTrials.gov, Number NCT03945292).
View article: Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy” Open
View article: Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication” Open
Infection with chronic Hepatitis C virus (HCV) has been a major cause of hepatocellular carcinoma (HCC) worldwide.In patients with active viral cirrhosis , there is a 2-5% annual incidence of HCC 1 .The development of direct-acting antivir…
View article: Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses Open
Approved treatments for chronic hepatitis B virus infection (cHBV) suppress viral replication, but viral rebound is almost always observed after treatment discontinuation, highlighting an unmet need for improved therapies with finite treat…
View article: Immunoglobulin G4-Seronegative Autoimmune Cholangiopathy With Pancreatic and Hepatic Involvement Mimicking as Primary Sclerosing Cholangitis
Immunoglobulin G4-Seronegative Autoimmune Cholangiopathy With Pancreatic and Hepatic Involvement Mimicking as Primary Sclerosing Cholangitis Open
Immunoglobulin G4-seronegative autoimmune cholangiopathy is a rare cause of biliary strictures. We describe a 27-year-old man presenting with elevated liver enzymes, recurrent cholangitis/bacteremia, biliary strictures, and normal immunogl…
View article: Vasoconstrictor Therapy for Acute Kidney Injury Hepatorenal Syndrome: A Meta-Analysis of Randomized Studies
Vasoconstrictor Therapy for Acute Kidney Injury Hepatorenal Syndrome: A Meta-Analysis of Randomized Studies Open
BACKGROUND AND AIMS: Type 1 hepatorenal syndrome (HRS) is a rapid deterioration in kidney function in patients with cirrhosis. Data on efficacy of vasoconstrictors for type 1 HRS have shown mixed results. METHODS: Literature searched for r…
View article: Issue Information
Issue Information Open
View article: It Is Time for a Simplified Approach to Hepatitis B Elimination
It Is Time for a Simplified Approach to Hepatitis B Elimination Open
View article: Epidemiology and Disease Burden of Alcohol Associated Liver Disease
Epidemiology and Disease Burden of Alcohol Associated Liver Disease Open
View article: Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites
Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites Open
Background Malignancy-related ascites accounts for approximately 10% of causes of ascites. Our AIM was to characterize the ascites fluid and correlate clinical outcomes in those with extrahepatic malignancy and ascites. Methods 241 subject…
View article: Mortality in patients with end‐stage liver disease above model for end‐stage liver disease 3.0 of 40
Mortality in patients with end‐stage liver disease above model for end‐stage liver disease 3.0 of 40 Open
Background and Aims: Since the implementation of the model for end‐stage liver disease (MELD) score to determine waitlist priority for liver transplant (LT) in 2002, the score has been capped at 40. Recently, the MELD 3.0 score was propose…
View article: Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy
Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy Open
Chronic hepatitis B virus (HBV) infection is the leading risk factor for hepatocellular carcinoma (HCC). The aim of this study was to explore the incidence of HCC in a cohort of subjects with HBV and correlate with HBV treatment current gu…
View article: Impact of COVID-19 on Liver Transplant Activity in the USA: Variation by Etiology and Cirrhosis Complications
Impact of COVID-19 on Liver Transplant Activity in the USA: Variation by Etiology and Cirrhosis Complications Open
The COVID-19 pandemic has impacted LT activity, with a decrease of LTs especially for HCC, and an increase of LTs for ALD and severe ACLF. Strategies are needed to reorganize cirrhosis patients to overcome the aftereffects of COVID-19 pand…
View article: Use and outcomes of hepatitis B virus–positive grafts in orthotopic liver transplantation in the United States from 1999 to 2021
Use and outcomes of hepatitis B virus–positive grafts in orthotopic liver transplantation in the United States from 1999 to 2021 Open
The demand for orthotopic liver transplantation (OLT) is projected to increase, which indicates a need to expand the liver donor pool. We aimed to investigate the use of hepatitis B virus (HBV)–positive grafts and the outcomes of recipient…
View article: Impact of COVID-19 on the liver transplant activity in the US: variation by the region, etiology, and cirrhosis complications
Impact of COVID-19 on the liver transplant activity in the US: variation by the region, etiology, and cirrhosis complications Open
View article: Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection Open
NCT03577171 LAY SUMMARY: Hepatitis B is a long-lasting viral infection of the liver. Current treatments can suppress hepatitis B virus but do not offer the opportunity of cure, hence, new treatment approaches are required. Herein, we show …
View article: Impact of medical eligibility criteria and OPTN policy on simultaneous liver kidney allocation and utilization
Impact of medical eligibility criteria and OPTN policy on simultaneous liver kidney allocation and utilization Open
Background Organ Procurement and Transplantation Network (OPTN) implemented medical eligibility and safety‐net policy on 8/10/17 to optimize simultaneous liver‐kidney (SLK) utilization. We examined impact of this policy on SLK listings and…
View article: First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide
First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide Open
Real‐world data are limited on tenofovir alafenamide (TAF). We aimed to study TAF real‐world outcomes with other first‐line regimens for chronic hepatitis B (CHB). We enrolled patients with CHB from 10 centers retrospectively and followed …
View article: Clinical Characteristics and Outcomes in Those with Primary Extrahepatic Malignancy and Malignant Ascites
Clinical Characteristics and Outcomes in Those with Primary Extrahepatic Malignancy and Malignant Ascites Open
Background: Malignancy-related ascites accounts for approximately 10% of causes of ascites. Our AIM was to characterize the ascites fluid and correlate clinical outcomes in those with extrahepatic malignancy and ascites. Results:241 subjec…